Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apricoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 9/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apricoxib SCHEMBL3435344 | 1.00 | CA1 (0.60) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5314130 | 0.90 | CA9 (0.62) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2841663 | 0.88 | PTGS2 (0.60) | CA1CA2CA9CA12CA7 | |
| SCHEMBL347479 | 0.86 | CA1 (0.59) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2463842 | 0.86 | CA1 (0.59) | CA1CA2CA9CA12CA7 | |
| SCHEMBL347020 | 0.84 | PTGS2 (0.58) | CA1CA2CA9CA12CA7 | |
| SCHEMBL13740431 | 0.84 | LMNA (0.48) | — | |
| SCHEMBL5312529 | 0.84 | PTGS2 (0.58) | CA1CA2CA9CA12CA7 | |
| SCHEMBL17920087 | 0.82 | PTGS2 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5308912 | 0.82 | PTGS2 (0.64) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260069532-A1 | METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE | MEDINCELL S.A. (FR) | 2026-03-12 | — | — | US | claimed |
| EP-4704343-A2 | CONVERTER | STMicroelectronics International N.V. (CH) | 2026-03-04 | — | — | EP | claimed |
| US-12558309-B2 | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue | MEDINCELL S.A. (FR) | 2026-02-24 | — | — | US | claimed |
| WO-2025224317-A1 | A METHOD FOR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLE IN TOTAL KNEE REPLACEMENT | MEDINCELL S.A. (FR) | 2025-10-30 | — | — | WO | claimed |
| US-20250213523-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2025-07-03 | — | — | US | claimed |
| CN-119546293-A | Combination of HDAC inhibitors and statins for the treatment of pancreatic cancer | 国家癌症研究所IRCCS-G·帕斯卡莱基金会 | 2025-02-28 | — | — | CN | claimed |
| EP-4504165-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2025-02-12 | — | — | EP | claimed |
| CN-119371525-A | Anti-thyroglobulin antibody, kit and use | 深圳迈瑞生物医疗电子股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| EP-4374861-A2 | A METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE | MedinCell S.A. (FR) | 2024-05-29 | — | — | EP | claimed |
| WO-2009009778-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | claimed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | claimed |
| US-20050272755-A1 | Method for treating abnormal cell growth | PFIZER INC | 2005-12-08 | — | — | US | claimed |
| US-6887893-B1 | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-05-03 | — | — | US | claimed |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED (JP) | 2005-01-20 | — | — | US | claimed |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | SANKYO COMPANY, LIMITED | 2005-01-06 | — | — | US | claimed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | claimed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | claimed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069532-A1 | METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE | MATR3, FUS, CD44 | PTGS2 1688/4885CA1 605/4885CA2 1254/4885 |
| US-20050272755-A1 | Method for treating abnormal cell growth | CCNI, MKI67, TOP2A | PTGS2 14/4885CA1 309/4885CA2 104/4885 |
| US-20050014814-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | PTGS2 4/4885CA1 981/4885CA2 520/4885 |
| US-12558309-B2 | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue | LOX, MMP12, ALOX12 | PTGS2 17/4885CA1 792/4885CA2 1197/4885 |
| US-20050004109-A1 | Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia | CPT1B, PYGM, PTGES2 | PTGS2 4/4885CA1 981/4885CA2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.